Caribou Biosciences, Inc. CRBU
1.24
(0.01)
(0.80%)
as of 25 Sep
- Market cap
- $134.0M
- P/E
- 0.0×
Follow CRBU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.71 | 16.26 | 13.31 | 23.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.80) | (6.75) | (7.13) | (8.63) | |
P/B ratio |
1.81 | 1.79 | 1.22 | 1.53 | |
Price to Tangible BV |
1.81 | 1.79 | 1.22 | 1.53 | |
EV/Sales |
6.52 | 5.76 | 0.82 | 7.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.68) | (0.64) | (0.08) | (0.56) | |
EV/FCF |
(0.49) | (0.63) | (0.08) | (0.55) | |
Quick Ratio |
6.32 | 6.06 | 5.56 | 5.32 | |
Current Ratio |
6.49 | 6.22 | 5.71 | 5.54 | |
Net Debt/EBITDA |
4.54 | 4.54 | 4.99 | 5.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.05 | 0.05 | 0.03 | |
Operating CF/Net income |
0.94 | 1.08 | 0.79 | 0.91 | |
Capex/Depreciation |
147.31 | (0.19) | 0.41 | (309.96) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,263.64% | 859.87% | 604.29% | 1,019.15% | |
Selling, General and Administrative Expense of Revenue |
526.75% | 336.50% | 217.69% | 418.43% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
165.24% | 98.33% | 69.47% | 133.35% | |
Graham Net Nets |
0.40 | 0.41 | 0.62 | 0.47 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(61.36%) | (74.74%) | (100.00%) | (72.96%) | |
Free Cash Flow Yield |
(74.71%) | (55.80%) | (75.66%) | (58.76%) | |
Revenue per Share |
0.01 | 0.03 | 0.04 | 0.02 | |
Operating CF per Share |
(0.23) | (0.28) | (0.22) | (0.27) | |
Capex per Share |
0.85 | 0.00 | 0.00 | (1.32) | |
Free Cash Flow per Share |
0.62 | (0.28) | (0.22) | (1.59) | |
Cash per Share |
1.11 | 1.23 | 1.49 | 1.58 | |
Shareholders Equity per Share |
0.97 | 1.06 | 1.31 | 1.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.06 | 1.31 | 1.52 | |
Free Cash Flow |
62.80 | (27.06) | (20.61) | (147.93) | |
Working Capital |
98.62 | 102.71 | 119.82 | 127.45 | |
Capital Expenditures |
85.59 | (0.07) | 0.22 | (122.74) | |
Net Current Asset Value |
71.92 | 75.40 | 92.04 | 102.37 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(57.10) | 0.03 | (0.05) | 55.84 | |
Net Profit Margin |
(1,619.88%) | (1,046.52%) | (672.11%) | (1,253.32%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.68 | 1.80 | 2.03 | 1.97 | |
Average Payables |
3.16 | 3.69 | 4.13 | 3.25 | |
Average Assets |
181.84 | 211.33 | 244.34 | 269.66 | |
Average Common Equity |
132.12 | 159.62 | 187.56 | 211.52 |
Columns are period end dates